Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 107 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Insulin-Like Growth Factor-1 (IGF-1) Clear all

Conditions: Disorder of Bone Density and Structure, Unspecified
Interventions: Recombinant human insulin like growth factor-1 (rhIGF-1); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 26 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injury
Interventions: Baclofen; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 20 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Acromegaly
Interventions: Debio 4126, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LoBag Diet - test phase, LoBAG Diet - control phase; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 55 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Insulin Resistance
Interventions: Placebo, Resveratrol; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Growth Hormone Insensitivity Syndrome
Interventions: mecasermin; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2011
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Gulf War Syndrome, Adult Growth Hormone Deficiency
Interventions: Recombinant human growth hormone; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Cystic Fibrosis
Interventions: Nutropin AQ; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions: teprotumumab, normal saline; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Thyroid Eye Disease
Interventions: VRDN-003, Autoinjector; Drug · Device
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Inglewood, California • Cape Coral, Florida • Kissimmee, Florida + 7 more

Conditions: Vitamin Deficiency
Interventions: EZPAK, Placebo; Dietary Supplement
Lead sponsor: Optimal Health Research; Other
Eligibility: 26 Years to 75 Years
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Mexican or American foods; Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bone; Disorder, Development and Growth
Interventions: Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Myotonic Dystrophy
Interventions: SomatoKine/IPLEX; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acromegaly
Interventions: Pasireotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • New York, New York

Conditions: Crohns Disease
Interventions: Examinations; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 5 Years to 15 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Autism Spectrum Disorder
Interventions: IGF-1, Placebo/saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 5 Years to 12 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Acromegaly
Interventions: Octreotide; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Alteration of Cognitive Function
Interventions: Exercise Challenge; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
Interventions: Dasatinib, Ganitumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • Bethesda, Maryland

Conditions: Phelan McDermid Syndrome
Interventions: Recombinant human Growth hormone; Drug
Lead sponsor: Swathi Sethuram; Other
Eligibility: 2 Years to 12 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Thyroid Eye Disease
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 37
States / cities: Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 27 more

Conditions: AIDS, HIV Infections
Interventions: recombinant human growth hormone, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa

Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)

Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome

Long-Term Treatment With rhIGF-1 in GHIS

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

Growth Hormone Therapy for Wasting in Cystic Fibrosis

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Effectiveness of a Nutraceutical in Raising Circulating Serum Vitamin, Mineral and Amino Acid Levels in Patients.

COMIDAS Comparing Original Mexican Diets and Standard US Diets

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

Impaired Insulin-like Growth Factor-1 (IGF-1) Generation Causes Protein Catabolism and Poor Growth in Children With Crohn Disease

A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

Exercise and Cognition Trials

Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Growth Hormone Treatment in Children With Phelan McDermid Syndrome

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

Physiologic Growth Hormone Effects in HIV Lipodystrophy